A Fading Thymus Hormone Made Cancer Immunotherapy Work Better in Older Mice

Cancer immunotherapy can deliver remarkable results, but age changes the immune system and may make treatment less effective. A new study points to an overlooked organ behind the breastbone and a hormone that fades as we grow older.

The effect was age-dependent: thymulin produced strong benefits in older mice but little effect in young mice.

Why age can change the fight against cancer

Low-level inflammation rises in many people as they age. This process, often called inflammaging, is linked with cardiovascular disease, neurodegeneration and cancer. Inside a tumour, inflammatory myeloid cells can also suppress the T cells that immunotherapy is trying to activate.

The researchers examined blood and tumour samples from mice and analysed human data. They found more inflammation-producing myeloid cells with age, including cells releasing IL-1, IL-6 and TNF signals. Older human breast tumours showed a similar inflammatory pattern, although this observation alone does not establish cause.

The small organ that may be doing more than expected

The thymus is best known as the place where T cells mature early in life. It shrinks with age and was once treated as relatively unimportant in adulthood. Evidence is increasingly challenging that assumption.

To find circulating factors that restrain inflammation, the team used experiments in which young and old mice shared circulation, along with bone marrow transfers and molecular analysis. The trail led to thymulin, a nine-amino-acid hormone produced by the thymus whose circulating activity declines with age.

In cells from older mice, thymulin reduced inflammatory signalling through a pathway called NF-kappa B. That matters because this pathway controls several cytokines that can create a tumour-friendly inflammatory environment.

What happened when thymulin met immunotherapy

The researchers tested several breast tumour models in aged mice. Thymulin reduced inflammatory myeloid cells, increased antitumour T-cell activity, delayed tumour growth and improved survival. Its effect was far smaller in young animals, suggesting that it was repairing an age-related deficit rather than simply stimulating every immune system.

The most striking result came when thymulin was combined with an anti-PD-L1 checkpoint inhibitor. Tumours in older mice that did not respond meaningfully to the checkpoint drug alone became more responsive when thymulin was added.

Why the study could change how medicines are tested

Preclinical cancer research often uses young mice because they are cheaper, easier to obtain and faster to study. Most people who develop cancer are much older. If age-related inflammation changes both tumour growth and drug response, young-animal experiments may miss treatments that help older immune systems or exaggerate treatments that work only in youth.

The finding therefore offers two ideas. Thymulin itself could become a therapeutic candidate, and ageing should be treated as a biological variable in cancer research rather than a detail to be added later.

What researchers need to prove next

The next steps include testing whether thymulin affects the formation and spread of different cancers, defining which older patients have the relevant inflammatory profile, and checking whether the hormone can be delivered safely. The deeper lesson is already useful: an ageing immune system is not merely a weaker version of a young one. It can be biologically different, and future therapies may work better when designed for that reality.